NDA 011909 · Parke Davis
Nardil
Phenelzine Sulfate · Oral
NovelLast checked: Nov 20, 2026Latest source record: Aug 2, 2007 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1961
Jun 9, 1961
Approved uses
1
Original approval plus efficacy supplements
Registered trials
11
0 Phase 3, 0 recruiting
FAERS reports
1,575
904 serious, 41 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of Nardil or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for...
What it is approved for
From the label in effect Nov 5, 2026.
INDICATIONS AND USAGE NARDIL has been found to be effective in depressed patients clinically characterized as "atypical," "nonendogenous," or "neurotic." These patients often have mixed anxiety and depression and phobic or hypochondriacal features. There is less conclusive evidence of its usefulness with severely depressed patients with endogenous features. NARDIL should rarely be the first antidepressant drug used. Rather, it is more suitable for use with patients who have failed to respond to the drugs more commonly used for these conditions.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 9, 1961 Original approval · Type 1 - New Molecular Entity
1 products under this application
- NARDIL · PHENELZINE SULFATE EQ 15MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Phenelzine" as an intervention, any sponsor and status, largest first.
- Precision Care for Major Depressive DisorderPivotal-lookingEnrolling by invitation
University of California, San FranciscoAcademic, hospital or other
NCT06580041 · 150 participants (planned) · Start Nov 12, 2024 · Primary completion Sep 1, 2029
Drug: Pramipexole; Methylphenidate and 1 more · For: Major Depressive Disorder; Depression; Depressive Disorder, Major
Sites: San Francisco, California
- Study to Evaluate the Pressor Effect of Oral Tyramine During Ozanimod Treatment in Healthy Adult ParticipantsPivotal-lookingCompleted
CelgeneBristol Myers Squibb (BMY)
NCT04978298 · 128 participants · Start Jul 19, 2021 · Primary completion Feb 26, 2023
Drug: Rasigiline; Phenelzine and 1 more · For: Healthy Volunteers
Sites: Anaheim, California
- Drug-drug Interaction Study of Ozanimod With Tyramine to Evaluate the Effect on Pressor ResponseCompleted
CelgeneBristol Myers Squibb (BMY)
NCT03694119 · 92 participants · Start Jul 24, 2018 · Primary completion Jan 8, 2019
Drug: Phenelzine; Tyramine and 3 more · For: Healthy Volunteer
Sites: Austin, Texas
- Efficacy of Hydroxyzine for Patients With Panic DisorderNot yet recruiting
Sultan Qaboos UniversityAcademic, hospital or other
NCT05737511 · 80 participants (planned) · Start Dec 30, 2023 · Primary completion Dec 30, 2026
Drug: Hydroxyzine; Escitalopram Oxalate · For: Panic Disorder
- A Study in Healthy People to Test How Combining BI 1467335 and Tyramine Affects Blood PressureTerminated
Boehringer IngelheimBoehringer Ingelheim
NCT03979820 · 53 participants · Start Jul 31, 2019 · Primary completion Apr 8, 2020
Drug: BI 1467335; Placebo and 2 more · For: Healthy
Sites: Groningen, Netherlands
Duke UniversityAcademic, hospital or other
NCT00612807 · 42 participants · Start Jul 2006 · Primary completion Jun 2010
Drug: As indicated: Sertraline, bupropion, venlafaxine, mirtazepine, nortriptyline, tranylcypromine, lithium augmentation, etc. · For: Major Depressive Disorder; Partner Relational Disorder (V61.10)
Sites: Durham, North Carolina
University of Southern CaliforniaAcademic, hospital or other
NCT02217709 · 26 participants · Start Sep 8, 2014 · Primary completion Jun 29, 2020
Drug: phenelzine sulfate · For: Adenocarcinoma of the Prostate; Recurrent Prostate Cancer; Stage I Prostate Cancer and 3 more
Sites: Beverly Hills, California; Los Angeles, California; Pasadena, California · 4 sites in all
OHSU Knight Cancer InstituteAcademic, hospital or other
NCT01253642 · 11 participants · Start Jul 12, 2010 · Primary completion Sep 15, 2016
Drug: Docetaxel; Phenelzine Sulfate · For: Hormone-Resistant Prostate Cancer; Metastatic Prostatic Adenocarcinoma; Prostate Adenocarcinoma and 1 more
Sites: Portland, Oregon; Seattle, Washington · 3 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective330
- depression187
- headache138
- anxiety129
- weight increased122
- insomnia104
- dizziness100
- drug interaction100
- pharmaceutical product complaint97
- fatigue94
- feeling abnormal89
- malaise78
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 106 |
| 2005 | 86 |
| 2006 | 53 |
| 2007 | 53 |
| 2008 | 50 |
| 2009 | 40 |
| 2010 | 187 |
| 2011 | 88 |
| 2012 | 98 |
| 2013 | 59 |
| 2014 | 65 |
| 2015 | 91 |
| 2016 | 57 |
| 2017 | 66 |
| 2018 | 68 |
| 2019 | 42 |
| 2020 | 121 |
| 2021 | 95 |
| 2022 | 27 |
| 2023 | 42 |
| 2024 | 39 |
| 2025 | 19 |
| 2026 | 23 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Nardil (Phenelzine Sulfate)
2024 spending
$107K
Beneficiaries
52
235 claims
Per beneficiary
$2,066
$2.44 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $276,138 |
| 2021 | $103,708 |
| 2022 | $130,721 |
| 2023 | $116,313 |
| 2024 | $107,431 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Interactions between herbal medicines and prescribed drugs: an updated systematic review.
Izzo AA, Ernst E · Drugs 2009 · Systematic Review
- Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis.
Serretti A, Chiesa A · J Clin Psychopharmacol 2009 · Meta-Analysis, Review
- Post-traumatic stress disorder.
Bisson JI · BMJ Clin Evid 2007 · Systematic Review
- Post-traumatic stress disorder.
Bisson JI · BMJ Clin Evid 2010 · Systematic Review
- Psychopharmacologic validation of atypical depression.
Liebowitz MR, Quitkin FM, Stewart JW, et al. · J Clin Psychiatry 1984 · Clinical Trial, Randomized Controlled Trial
- How treatable is refractory depression?
Stewart JW, Deliyannides DA, McGrath PJ · J Affect Disord 2014 · Clinical Trial, Research Support, Non-U.S. Gov't
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.